US Patent

US7378423 — Pyrimidine compound and medical use thereof

Composition of Matter · Assigned to Japan Tobacco Inc · Expires 2027-05-29 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a pyrimidine compound represented by formula [I] and its use in treating undesirable cell proliferation, particularly cancer.

USPTO Abstract

The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.

Drugs covered by this patent

Patent Metadata

Patent number
US7378423
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-05-29
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Japan Tobacco Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.